- Conditions
- Schizophrenia
- Interventions
- SPD489 (Lisdexamfetamine dimesylate), Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Glendale, California • Long Beach, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–39
of 39
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- PRC-063, lisdexamfetamine dimesylate, Placebo
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Schizophrenia
- Interventions
- SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 4
- States / cities
- Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more
- Conditions
- Schizophrenia
- Interventions
- SPD489 40mg, SPD489 100mg, SPD489 160mg, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Irving, Texas
- Conditions
- Attention-deficit/Hyperactivity Disorder
- Interventions
- Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 79
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 68 more
- Conditions
- Binge-Eating Disorder, Obesity
- Interventions
- Lisdexamfetamine Dimesylate, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Binge Eating Disorder
- Interventions
- Lisdexamfetamine
- Drug
- Lead sponsor
- Lindner Center of HOPE
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Mason, Ohio
- Conditions
- ADHD
- Interventions
- SPD489, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 13 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Bradenton, Florida • Overland Park, Kansas + 3 more
- Conditions
- Attention-deficit/Hyperactivity Disorder
- Interventions
- lisdexamfetamine dimesylate, Placebo
- Drug
- Lead sponsor
- University of Rhode Island
- Other
- Eligibility
- 18 Years to 28 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Bethlehem, Pennsylvania • Kingston, Rhode Island
- Conditions
- Chronic Fatigue Syndrome, Cognitive Impairments
- Interventions
- Lisdexamfetamine Dimesylate, Placebo "30, 50 or 70 mg"
- Drug
- Lead sponsor
- Rochester Center for Behavioral Medicine
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Rochester Hills, Michigan
- Conditions
- Menopause, Brain Activity, Cognition
- Interventions
- Lisdexamfetamine, Placebo
- Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 45 Years to 60 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Binge Eating Disorder
- Interventions
- SPD489 (Lisdexamfetamine dimesylate), Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 45
- States / cities
- Tucson, Arizona • Beverly Hills, California • La Jolla, California + 42 more
- Conditions
- Attention Deficit Hyperactivity Disorder, Glucose Intolerance, Obesity
- Interventions
- Lis-dexamphetamine
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Binge Eating Disorder
- Interventions
- Lisdexamfetamine dimesylate
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 77 more
- Conditions
- Attention-deficit/Hyperactivity Disorder
- Interventions
- Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 81
- States / cities
- Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 68 more